CIK 0000200406 · Large accelerated filer
JOHNSON & JOHNSON
Sign in to watch- Ticker
- JNJ
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Jan 3
- Incorporated
- NJ
- Entity type
- operating
- EIN
- 221024240
- Phone
- 732-524-2455
- Business address
- ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK, NJ, 08933
- Former names
- JOHNSON & JOHNSON ET AL
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $16,898,386
- in 3 filings
Net −$16,898,386. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-18 | Schmid Timothy EVP, WW Chair, MedTech | Sale | −8,998 | $244.53 | $2.2M | 26,769 |
| 2026-02-18 | Schmid Timothy EVP, WW Chair, MedTech | Option exercise · Employee Stock Options (Right to Buy) | −13,625 | 0 | ||
| 2026-02-18 | Schmid Timothy EVP, WW Chair, MedTech | Option exercise · Employee Stock Options (Right to Buy) | −8,998 | 0 | ||
| 2026-02-17 | Swanson James D. EVP, CIO | Option exercise | +20,521 | $164.62 | $3.4M | 46,219.13 |
| 2026-02-17 | Swanson James D. EVP, CIO | Sale | −20,521 | $242.70 | $5.0M | 25,698.13 |
| 2026-02-17 | Swanson James D. EVP, CIO | Option exercise · Employee Stock Options (Right to Buy) | −20,521 | 0 | ||
| 2026-02-17 | Wolk Joseph J Exec VP, CFO | Option exercise | +19,241 | $115.67 | $2.2M | 58,202 |
| 2026-02-17 | Wolk Joseph J Exec VP, CFO | Sale | −19,241 | $242.99 | $4.7M | 38,961 |
| 2026-02-17 | Wolk Joseph J Exec VP, CFO | Option exercise | +12,066 | $129.51 | $1.6M | 51,027 |
| 2026-02-17 | Wolk Joseph J Exec VP, CFO | Sale | −12,066 | $242.87 | $2.9M | 38,961 |
| 2026-02-17 | Wolk Joseph J Exec VP, CFO | Option exercise | +33,386 | $131.94 | $4.4M | 72,347 |
| 2026-02-17 | Wolk Joseph J Exec VP, CFO | Sale | −33,386 | $242.75 | $8.1M | 38,961 |
| 2026-02-17 | Wolk Joseph J Exec VP, CFO | Sale | −24,961 | $242.68 | $6.1M | 14,000 |
| 2026-02-17 | Wolk Joseph J Exec VP, CFO | Option exercise · Employee Stock Options (Right to Buy) | −19,241 | 0 | ||
| 2026-02-17 | Wolk Joseph J Exec VP, CFO | Option exercise · Employee Stock Options (Right to Buy) | −12,066 | 0 | ||
| 2026-02-17 | Wolk Joseph J Exec VP, CFO | Option exercise · Employee Stock Options (Right to Buy) | −33,386 | 33,000 | ||
| 2026-02-17 | REED JOHN C EVP, Innovative Medicine, R&D | Option exercise | +21,721 | $157.92 | $3.4M | 34,662 |
| 2026-02-17 | REED JOHN C EVP, Innovative Medicine, R&D | Sale | −21,721 | $243.00 | $5.3M | 12,941 |
| 2026-02-17 | REED JOHN C EVP, Innovative Medicine, R&D | Option exercise | +29,927 | $156.15 | $4.7M | 42,868 |
| 2026-02-17 | REED JOHN C EVP, Innovative Medicine, R&D | Sale | −29,927 | $243.00 | $7.3M | 12,941 |
Page 4 of 19 · 365 trades